

ArcticZymes Technologies ASA Publishes Innovative Research on Novel RNA Restriction Enzyme, Paving the Way for Precision RNA Manipulation

Tromsø, Norway 16 September 2024 - ArcticZymes Technologies ASA, a leading developer and manufacturer of high-quality enzymes for molecular research, diagnostics, and therapeutics, is thrilled to announce the publication of a research paper in the prestigious international peer-reviewed journal *Nucleic Acid Research*. The paper, entitled "*Using nucleolytic toxins as restriction enzymes enables new RNA applications*," showcases the unique features and potential applications of a novel RNA restriction enzyme called ET-N1 (EcoToxN1).

Revolutionizing RNA Fragmentation: The patent-pending ET-N1 enzyme technology represents a significant advancement in the field of RNA research, enabling precise and controlled fragmentation of RNA molecules. This innovative tool opens up new possibilities for analyzing and synthesizing RNA, paving the way for the development of cutting-edge methodologies in the rapidly evolving field of RNA research and therapeutics.

Unique Capabilities: What sets ET-N1 apart from other commercialized enzymes is its ability to act as "molecular scissors," offering functions that no other enzyme can currently match. With the development of further variants, ArcticZymes Technologies ASA is poised to revolutionize the landscape of RNA modulation tools, empowering researchers and industry partners to push the boundaries of scientific discovery and therapeutic innovation.

Collaborative Effort: The research paper, authored by Rothweiler et al., is the result of a collaborative effort between ArcticZymes Technologies ASA and esteemed academic and research institutions, including the University of Tromsø, Norway, the Indian Institute of Science, Bangalore, India, and SINTEF Industry, Trondheim, Norway. This collaborative endeavor was made possible through the support of the Norwegian Research Council's innovation grant "AdEPT – Advanced Enzymes for Precision Therapeutics."

Driving Progress and Innovation: Emphasizing ArcticZymes commitment to driving progress and innovation in the field, CEO Michael Akoh comments: "*Through dissemination of our research findings in peer-reviewed journals, ArcticZymes aims to elevate awareness of our cutting-edge products and stimulate the emergence of disruptive technologies. We are committed to driving forward progress in the field, providing enzymes that unlock new discoveries enabling our partners' development of tomorrows innovative technologies*".

Read the paper here: [Using nucleolytic toxins as restriction enzymes enables new RNA applications | Nucleic Acids Research | Oxford Academic \(oup.com\)](#)

For more information, please contact:

ArcticZymes Technologies ASA

CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15

CFO, Børge Sørvoll Tel: +47 95 29 01 87

ir@arcticzymes.com



About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who developing therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customer's lives easier by unlocking new solutions to enhance quality of life and create a more sustainable, healthy world.